Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of...
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab) CAMBRIDGE, Mass...
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS SOD1-ALS is a rare, genetic...
Biogen Names Christopher Viehbacher President and Chief Executive Officer Distinguished Industry Leader Brings Extensive International...
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with...
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS Final safety...
Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen The new Prescription Drug User Fee Act...
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab) CAMBRIDGE, Mass., Sept. 30...
The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS Publication includes the...
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus...
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus Results from...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS SOD1-ALS is a rare genetic...
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) Patent covers approved dosing regimen for TECFIDERA and...
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.